1. Home
  2. TOPS vs CVKD Comparison

TOPS vs CVKD Comparison

Compare TOPS & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo TOP Ships Inc.

TOPS

TOP Ships Inc.

HOLD

Current Price

$0.90

Market Cap

15.0M

ML Signal

HOLD

Logo Cadrenal Therapeutics Inc.

CVKD

Cadrenal Therapeutics Inc.

HOLD

Current Price

$4.96

Market Cap

15.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TOPS
CVKD
Founded
2000
2022
Country
Greece
United States
Employees
N/A
5
Industry
Marine Transportation
Medicinal Chemicals and Botanical Products
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
15.0M
15.3M
IPO Year
2004
2022

Fundamental Metrics

Financial Performance
Metric
TOPS
CVKD
Price
$0.90
$4.96
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$13.00
AVG Volume (30 Days)
1.1M
63.4K
Earning Date
04-01-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.94
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$2.14
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.88
$4.21
52 Week High
$11.47
$15.99

Technical Indicators

Market Signals
Indicator
TOPS
CVKD
Relative Strength Index (RSI) 18.26 41.30
Support Level N/A $4.21
Resistance Level $6.18 $6.09
Average True Range (ATR) 0.23 0.53
MACD 0.01 -0.04
Stochastic Oscillator 1.36 7.24

Price Performance

Historical Comparison
TOPS
CVKD

About TOPS TOP Ships Inc.

TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.

Share on Social Networks: